The Oncology Institute, Inc. (NASDAQ:TOI) Short Interest Up 86.8% in December

The Oncology Institute, Inc. (NASDAQ:TOI) was the recipient of a large increase in short interest in the month of December. As of December 31st, there was short interest totalling 324,100 shares, an increase of 86.8% from the December 15th total of 173,500 shares. Based on an average trading volume of 1,740,000 shares, the days-to-cover ratio is presently 0.2 days. Currently, 0.9% of the shares of the company are sold short.

Oncology Institute Price Performance

Shares of Oncology Institute stock opened at $0.31 on Tuesday. The stock has a market capitalization of $23.55 million, a price-to-earnings ratio of -0.40 and a beta of 0.43. Oncology Institute has a 1-year low of $0.13 and a 1-year high of $2.45. The company has a current ratio of 2.49, a quick ratio of 2.27 and a debt-to-equity ratio of 5.91. The firm has a fifty day simple moving average of $0.23 and a 200-day simple moving average of $0.33.

Insider Activity at Oncology Institute

In related news, Director Brad Hively acquired 250,000 shares of the business’s stock in a transaction on Tuesday, November 26th. The shares were purchased at an average price of $0.17 per share, for a total transaction of $42,500.00. Following the acquisition, the director now owns 616,753 shares in the company, valued at approximately $104,848.01. This represents a 68.17 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 9.50% of the stock is owned by insiders.

Institutional Trading of Oncology Institute

An institutional investor recently raised its position in Oncology Institute stock. HighTower Advisors LLC increased its position in shares of The Oncology Institute, Inc. (NASDAQ:TOI) by 190.8% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 81,362 shares of the company’s stock after buying an additional 53,382 shares during the quarter. HighTower Advisors LLC owned 0.11% of Oncology Institute worth $27,000 at the end of the most recent quarter. Institutional investors own 36.86% of the company’s stock.

About Oncology Institute

The Oncology Institute, Inc, an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services.